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Figure S1. Cdc60-Gtr1 Interaction in the Absence of Gtr2, Related to Figure 1 
Gtr1-TAP, or the control protein Igo1-TAP, was precipitated from extracts of Cdc60-HA3-expressing wild-
type (WT) or gtr2¨ cells that were grown to and harvested in exponential growth phase. Cell lysates 
(Input) and TAP pull-down fractions were subjected to SDS-PAGE and immunoblots were probed with 
anti-HA or anti-protein A (anti-TAP) antibodies as indicated. 
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Figure S2. Additional Effects of DHBB Treatment, Related to Figure 2 
(A and B) DHBB treatment does not affect the localization of Gtr1-GFP (A) or Tor1-GFP (B). Gtr1-GFP 
(A) and Tor1-GFP (B) mainly localize to the vacuolar membrane, while Cdc60-RFP (A) adjoins the 
limiting membrane of the vacuole, but mainly localizes to the cytoplasm in exponentially growing cells 
(EXP). DHBB (10 M) treatment does not detectably alter the localization of Gtr1-GFP, Tor1-GFP, or 
Cdc60-RFP. Notably, given the high abundance of Cdc60-RFP within the cytoplasm, a potential DHBB-
induced displacement of Cdc60-RFP from the vacuolar membrane may escape detection by standard 
fluorescence microscopic analyses. Tr, transmission. 
(C) DHBB disrupts the Cdc60-Gtr1GTP interaction in a concentration-dependent manner. Gtr1GTP-TAP was 
precipitated from cells co-expressing Cdc60-HA3. Cells were harvested in exponential growth phase either 
prior to (0) or following a 30-min period of treatment with the indicated DHBB concentrations. Cell 
lysates (Input) and TAP pull-down fractions were subjected to SDS-PAGE and immunoblots were probed 
with anti-HA or anti-protein A (anti-TAP) antibodies. 
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Figure S3. Physiological Relevance of LeuRS Editing, Related to Figure 4 
(A) Leucine starvation causes TORC1 inactivation in both wild-type and cdc60D419A mutant cells. Leucine 
(leu2¨) auxotrophic wild-type (WT) and cdc60D419A mutant cells were grown to exponential phase in 
medium containing leucine and then transferred to a medium lacking leucine (0 time point). Samples were 
taken at the times indicated following leucine starvation and TORC1 activity was assayed as in Figure 1D. 
(B) Temperature-inactivation of Cdc60ts protects TORC1 from leucine starvation-induced downregulation. 
Leucine (leu2¨) auxotrophic wild-type and cdc60ts mutant cells were grown to exponential phase in 
medium containing leucine, incubated for 1 hr at either 30°C or 37°C, and then transferred to a medium 
lacking leucine (0 time point). Samples were taken at the times indicated following leucine starvation (-
Leu) and TORC1 activity was assayed as in Figure 1D. Data are expressed as relative values with respect 
to the 0 time point and reported as averages (n = 3), with standard deviations indicated by the lines above 
each bar. As assessed by two-way analysis of variance (ANOVA) followed by post-test analysis, the 
observed differences between wild-type and cdc60ts cells at 37°C are statistically significant with p-values 
< 0.05 (indicated with one asterisk). 
(C) Addition of isoleucine in disproportionate quantities causes transient TORC1 inactivation. Wild-type 
cells were grown (on SD medium) to exponential growth phase and treated with excessive amounts of 
isoleucine (i.e. final concentration of 53 mM). Samples were taken at the times indicated following 
isoleucine addition and TORC1 activity was assayed as in Figure 1D. 
(D) LeuRS editing is specifically required for growth under leucine limiting conditions. Leucine (leu2¨)
and histidine (his3¨) auxotrophic wild-type (blue bars) and LeuRS editing defective cdc60D419A mutant 
(red bars) cells were grown in SD medium containing either 5 mM histidine and various levels of leucine 
(Leu [mM]), or 9 mM leucine and different levels of histidine (His [mM]) as indicated. Doubling times are 
reported as averages (n = 3), with standard deviations indicated by the lines above each bar. 
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Table S1. Proteins Identified in Gtr1-TAP Pull-Down Experiments, Related to Figure 1 
Protein1 Function No. of peptides 
(+ Leu) 
No. of peptides 
(- Leu) 
Rpl4A Component of the large (60S) ribosomal subunit 9 0 
Vas1 Mitochondrial and cytoplasmic valyl-tRNA synthetase 6 0 
Ded1 DEAD-box helicase 6 0 
Fas1 Fatty Acid synthetase 24 1 
Cdc60 Leucyl-tRNA synthetase 11 1 
Rpo21 DNA-directed RNA polymerase 9 1 
Gnd1 6-Phosphogluconate dehydrogenase 8 1 
Trr1 Thioredoxin reductase 6 1 
Faa4 Fatty acyl-CoA synthetase 5 1 
Acc1 Acetyl-CoA carboxylase 5 1 
Pfk2 Phosphofructokinase 5 1 
Rpn8 Regulatory subunit of the 26S proteasome 5 1 
Fet5 Multicopper oxidase 5 1 
1Proteins were identified by LC-MS-MS analysis of polypeptides in purified Gtr1-TAP preparations from exponentially 
growing (+Leu) or leucine-deprived (30 min; -Leu) cells. Only proteins for which at least one peptide was identified in the 
Gtr1-TAP preparations (confidence interval of 99.9%) and none in control preparations from non-tagged wild-type cells were 
retained for further analysis. Proteins for which at least 5 peptides were identified in the +Leu samples and none in the 
corresponding –Leu samples, or proteins for which the ratio of the number of peptides in the +Leu versus the -Leu samples was 
> than 5, were retained for this table. 
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Table S2. Strains Used in This Study 
Strain Genotype Source Figure 
BY4741 MATa; his3¨1 leu2¨0 ura3¨0 met15¨0 Euroscarf S3B 
BY4742 MATD; his3¨1 leu2¨0 ura3¨0 lys2¨0 Euroscarf
Y08149 [BY4741] MATa; cdc60ts Li et al., 2011 S3B 
YL515 [BY4741/2] MATD; his3ǻ1, leu2ǻ0, ura3ǻ0 Binda et al., 2009  
YL516 [BY4741/2] MATa; his3ǻ1, leu2ǻ0, ura3ǻ0 Binda et al., 2009 2A-C, 3A-D, 4C 
GB2381 [YL516] MATa; CDC60-HA3::HIS3 This study 
1A/B, 2D/E, S1, 
S2C 
GB2382 [YL516] MATa; IGO1-TAP-kanMX4, 
CDC60-HA3-HIS3
This study 1A, S1 
GB2549 [YL516] MATa; CDC60-HA3-HIS3, gtr2¨::kanMX4 This study S1 
GB2523 [YL516] MATa; KOG1-HA::kanMX4 This study 2F 
MPG1630 [YL516] MATa; gtr1¨::kanMX4, gtr2¨::kanMX4 This study 2A-C, 3B/C 
GB2378 [YL516] MATa; cdc60D418R This study 2A-C 
GB2379 [YL516] MATa; cdc60D418R- HA3::HIS3 This study 2E 
MB32 [YL516] MATa; gtr1¨::kanMX4 Binda et al., 2009 4A 
MJA2638 [YL515] MATD; cdc60¨::KanMX4
[YCplac111-CDC60]
This study 4A, S3A, S3D 
MJA2786 [YL515] MATD; cdc60¨::KanMX4
[YCplac111-CDC60D419A]
This study S3A, S3D, S3C 
MJA2784 [YL515] MATD; cdc60¨::KanMX4 
[CEN, HIS3, CDC60]
This study S3D 
MJA2785 [YL515] MATD; cdc60¨::KanMX4 
[CEN, HIS3, CDC60D419A]
This study S3D 
MJA2604 [YL515] MATD; cdc60¨::KanMX4 
[YCplac111-cdc60S414F]
This study 4A 
8003 MATD; leu2ǻ0, ura3, trp1, his3, ade8, cdc60ts Hohmann and 
Thevelein, 1992 
1C/D 
MPG2389 MATa; HIS3::GTR1-GFP, gtr1¨::natMX4, ura3-52, 
leu2, trp1 
This study S2A 
MP52-2A [YL516] MATa; TOR1-D330-3xGFP Binda et al., 2009 S2B 
NMY51 MATa; his3¨200, trp1-901, leu2-3,112, ade2, 
LYS::(lexAop)4-HIS3, ura3::(lexAop)8- lacZ, 
ade2::(lexAop)8-ADE2 GAL4 
Dualsystems 4B 

ht
tp
://
do
c.
re
ro
.c
h
Table S3. Plasmids Used in This Study
Plasmid Description Source Figure 
YCplac33 CEN, URA3 Gietz and Sugino, 1988 2A-C, 3A-D, 4A-D 
YCplac111 CEN, LEU2 Gietz and Sugino, 1988 2A-C, 3A-C, 4A 
pMB1344 YCplac33-GTR1-TAP Binda et al., 2009 1A-B, 2D-F, 4C, S1 
pCM264 CEN, URA3, TetOFF-HIS6-HA3 Arino and Herrero, 2003 1C/D, 4A 
pGB1957 pCM264-TetOFF-HIS6-CDC60 This study 1C/D 
pJU1462 pRS413-SCH9T570A-HA5 Urban et al., 2007 1D, 2A-C, 3A-D, 4D, 
S3C 
pMB1394 YCplac33-TetON-GTR1Q65L Binda et al., 2009 2A-C, 3B/C, 4A 
pPM1623 YCplac111-TetON-GTR2S23L This study 2A-C, 3B/C, 4A 
pMJ1974 YCplac111-CDC60 This study 4A, S3D 
pMJ2113 YCplac111-CDC60S414F This study 4A 
pDL2-Alg5 2, ADH1-HA-NubG, TRP1 Dualsystems 4B 
pAI-Alg5 2, ADH1-HA-NubI,TRP1 Dualsystems 4B 
pPR3-N 2, CYC1-NubG-HA, TRP1 Dualsystems 4B 
pNP1689 pPR3-N-CYC1-NubG-HA-GTR1 Binda et al., 2009 4B 
pNP1692 pPR3-N-CYC1-NubG-HA-GTR2 Binda et al., 2009 4B 
pMJ18681 pCabWT-CYC1-Cub-LexA-Cdc60CP1 This study 4B 
pMJ21151 pCabWT-CYC1-Cub-LexA-Cdc60CP1-S414F This study 4B 
pMPG1574 2, TetON-HIS6-HA3, URA3 Binda et al., 2009 4C/D 
pMJ20591 pMPG1574-TetON-HIS6-HA3-CDC60CP1 This study 4C/D 
pMJ21161 pMPG1574-TetON-HIS6-HA3-CDC60CP1-S414F This study 4C/D 
pMB1372 YCplac33- GTR1Q65L -TAP Binda et al., 2009 S2C 
pMJA2192 pRS416-CYC1-CDC60-RFP, URA3 This study S2A 
pMJA2069 YCplac111-CDC60D419A This study S3A, S3D 
pJU1436 pRS416-SCH9T570A-HA5 Urban et al., 2007 S3C 
pMJA2168 CEN, HIS3, CDC60 This study S3C, S3D 
pMJA2167 CEN, HIS3, CDC60D419A This study S3D 
1Plasmids pMJ1868/pMJ2115 and pMJ2059/pMJ2116 express the Cdc60 CP1 editing domain encompassing 
amino acids 263-548 and 263-530 of Cdc60, respectively. 
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